Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate‐to‐severe plaque psoriasis: Results from UNCOVER‐1, UNCOVER‐2, and UNCOVER‐3
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2018.02.074
Abstract: Background: The impact of ixekizumab treatment for psoriasis on cardiovascular‐related parameters in patients is unknown. Objective: To investigate cardiovascular‐related parameters in patients with psoriasis treated with ixekizumab. Methods: In phase 3 trials, patients with moderate‐to‐severe… read more here.
Keywords: parameters patients; impact; density lipoprotein; psoriasis ... See more keywords
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2016.1249820
Abstract: Abstract Background: Scalp is a frequently affected and difficult-to-treat area in psoriasis patients. Objective: We assessed the efficacy of ixekizumab in the treatment of patients with scalp psoriasis over 60 weeks using the Psoriasis Scalp… read more here.
Keywords: ixekizumab; treatment; severe psoriasis; psoriasis ... See more keywords